Shared on 09 Aug 25
Fair value Decreased 9.09%AI Diagnostic Solutions Will Transform Medical Imaging Globally
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).
Shared on 01 May 25
Fair value Decreased 7.56%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Shared on 23 Apr 25
Fair value Decreased 1.00%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 1.86%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 6.35%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 3.96%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 0.46%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.31%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 13 Mar 25
Fair value Increased 18%Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
AnalystConsensusTarget has increased revenue growth from 2.3% to 3.9%, increased profit margin from 14.3% to 20.9% and decreased future PE multiple from 25.6x to 19.1x.